Retrospective analysis of the pre-audit results for prescriptions of Chinese patent medicines in a second-level hospital
10.12206/j.issn.1006-0111.202111089
- VernacularTitle:对某二级医院中成药处方前置审核结果的回顾性分析
- Author:
Shanshan XU
1
;
Xiang FU
1
Author Information
1. Kongjiang Hospital of Yangpu District, Shanghai 200093, China.
- Keywords:
pre-prescription audit system;
Chinese patent medicine containing toxic ingredients;
medication risk
- From:
Journal of Pharmaceutical Practice
2022;40(4):379-382
- CountryChina
- Language:Chinese
-
Abstract:
Objective Analyze the pre-audit results of Chinese patent medicine prescriptions in a second-level hospital, suggest the risks of taking Chinese patent medicines and promote the safe and standardized use of Chinese patent medicines. Methods A total of 31542 outpatient and emergency prescriptions of Kongjiang hospital in April 2021 were collected, combined with the review of the instructions and relevant data, classify the toxic components of Chinese patent medicines, and summarize and analyze the problems of drug use. Results The types of problems in the prescription of Chinese patent medicine and chemical medicines were different, mainly including repeated medication and wrong usage and dosage. Insufficient warnings on toxic medicinal ingredients in the instructions of Chinese patent medicines and the imperfect knowledge base of audit software increased the risk of using Chinese patent medicines. Conclusion It is necessary to improve the knowledge base of the prescription audit system, strengthen the high-alarm management of Chinese patent medicines containing toxic ingredients, and improve the public's understanding of the rational use of Chinese patent medicines.
